Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sub-Sero: Pimavanserin in First-Episode Schizophrenia
NCT03994965Phase 2Withdrawn
- Start
- Dec 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of pimavanserin in schizophrenia. Planned start Dec 2024; status: withdrawn.
02
Drugs
pimavanserin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT03994965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03994965.